Special Section on Mechanistic and Translational Research on
Transporters in Toxicology

Attenuated Ochratoxin A Transporter Expression in a Mouse Model of Nonalcoholic Steatohepatitis Protects against Proximal Convoluted Tubule Toxicity

Joseph L. Jilek, Kayla L. Frost, Solène Marie, Cassandra M. Myers, Michael Goedken, Stephen H. Wright, and Nathan J. Cherrington

Department of Pharmacology and Toxicology, University of Arizona, College of Pharmacy, Tucson, Arizona (J.L.J., K.L.F., S.M., C.M.M., N.J.C.); Rutgers Translational Sciences, Rutgers University, Piscataway, New Jersey (M.G.); and Department of Physiology, University of Arizona, College of Medicine, Tucson, Arizona (S.H.W.)

ABSTRACT

Ochratoxin A (OTA) is an abundant mycotoxin, yet the toxicological impact of its disposition is not well studied. OTA is an organic anion transporter (OAT) substrate primarily excreted in urine despite a long half-life and extensive protein binding. Altered renal transporter expression during disease, including nonalcoholic steatohepatitis (NASH), may influence response to OTA exposure, but the impact of NASH on OTA toxicokinetics, tissue distribution, and associated nephrotoxicity is unknown. By inducing NASH in fast food-dieted/thioacetamide-exposed mice, we evaluated the effect of NASH on a bolus OTA exposure (12.5 mg/kg by mouth) after 3 days. NASH mice presented with less gross toxicity (44% less body weight loss), and renal and liver weights of NASH mice were 11% and 24% higher, respectively, than healthy mice. Organ and body weight changes coincided with reduced renal proximal tubule cells vacuolation, degeneration, and necrosis, though no OTA-induced hepatic lesions were found. OTA systemic exposure in NASH mice increased modestly from 5.65 ± 1.10 to 7.95 ± 0.61 mg*h/ml per kg BW, and renal excretion increased robustly from 5.55% ± 0.37% to 13.11% ± 3.10%, relative to healthy mice. Total urinary excretion of OTA increased from 24.41 ± 1.74 to 40.07 ± 9.19 μg in NASH mice, and kidney-bound OTA decreased by ~30%. Renal OAT isoform expression (OAT1–5) in NASH mice decreased by ~50% with reduced OTA uptake by proximal convoluted cells. These data suggest that NASH-induced OAT transporter reductions attenuate renal secretion and reabsorption of OTA, increasing OTA urinary excretion and reducing renal exposure, thereby reducing nephrotoxicity in NASH.

SIGNIFICANCE STATEMENT

These data suggest a disease-mediated transporter mechanism of altered tissue-specific toxicity after mycotoxin exposure, despite minimal systemic changes to ochratoxin A (OTA) concentrations. Further studies are warranted to evaluate the clinical relevance of this functional model and the potential effect of human nonalcoholic steatohepatitis on OTA and other organic anion substrate toxicity.

Introduction

Since the discovery of ochratoxin A (OTA) in 1965 (van der Merwe et al., 1965), the specific molecular mechanism of toxicity has yet to be determined (Malir et al., 2016). OTA is a well-known mycotoxin that primarily contaminates foodstuffs, which serve as the primary route of exposure (Santos et al., 2009; Palumbo et al., 2015; Malir et al., 2016). Ochratoxins are naturally occurring metaboliites produced by several fungi, including Aspergillus and Penicillium species, although OTA is considered the most toxic of the group (Bui-Klimke and Wu, 2015). Epidemiologic studies have linked OTA exposure to Balkan endemic nephropathy (Castegnaro et al., 2006; Yordanova et al., 2010), demonstrating that the kidney may be a target organ of toxicity. Indeed, given the prevalence of OTA in contaminated and spoiled foodstuffs, nephrotoxicity is a common finding in many animal species exposed to OTA, in addition to humans (Huff et al., 1975; Mally et al., 2005; Heussner and Bingle, 2015). Many mechanisms of toxic action have been proposed to explain OTA-induced renal damage (Simon et al., 1996), including apoptosis induction and reduced proximal tubule cell

This work was supported by National Institutes of Health National Institute of Environmental Health Sciences [Grant R01-ES028668], [Grant P30-ES006694], and [Grant T32-ES007091] (J.L.J.).

The authors declare they have no conflicts of interest with the contents of this article.
adhesion, metabolism dysregulation, disruption of cellular electrochemical and pH homeostasis, and oxidative stress induction (Gekle and Silbernagl, 1993; Gekle et al., 1995; Schwerdt et al., 1999; Limonciel and Jennings, 2014). Though most evidence suggests that OTA selectively damages proximal convoluted tubule epithelial cells, glomerular changes may accompany chronic OTA exposure (Gekle and Silbernagl, 1994). Furthermore, OTA is an immunotoxicant (Al-Anati and Petzinger, 2006) and is also genotoxic in multiple species, including humans, necessitating the need for enhanced understanding of chronic exposure (Pfohl-Leszkowicz and Manderville, 2007; Stoev, 2010).

Toxicokinetic properties of xenobiotics are common variables in drug disposition and toxicity because slower drug clearance may exacerbate toxicity by increasing exposure. Furthermore, changes to systemic exposure may not always predict target organ toxicity, as transport-mediated uptake may concentrate certain toxicants into specific organs due to transporter isoform distribution and substrate specificity (Shitara et al., 2006; Hagos and Wolff, 2010). As a major xenobiotic clearance organ, the kidney expresses many specific transporters along the length of the nephron. Specifically, several organic anion transporter (OAT) isoforms are heavily expressed in proximal convoluted tubule cells of the renal cortex, where most xenobiotic active secretion and reabsorption from filtrate occurs (Masereeuw and Russel, 2001). Namely, OAT1 and 3 are expressed on the basolateral (blood) side, and although both are functionally bidirectional, they predominately import endogenous and exogenous solutes in coupled exchange for intracellular z-ketoglutarate (Nigam et al., 2015; Ivanyuk et al., 2017; Huo and Liu, 2018). OTA is negatively charged at physiologic pH and is a known substrate for OAT1 and 3 (Jung et al., 2001). Apical efflux of organic anions, including OTA, may be facilitated by transepithelial transport mediated by multidrug resistance-associated proteins (MRP) isoforms, including MRP2 and 4 and breast cancer resistance protein (BCRP), which efflux substrates into the renal filtrate (Anzai et al., 2010). Although these processes are unidirectional, apical OAT isoforms (OAT2 and 5 in rodents and OAT4 in humans) may also remove organic anion solutes from the filtrate, reabsorbing them back into the proximal tubule cell (Cha et al., 2000; Youngblood and Sweet, 2004; Anzai et al., 2005; Shima et al., 2010). Taken together, OTA renal elimination is a sum of OAT1/3-mediated secretion into the proximal convoluted tubule cell, efflux via MRP isoforms into the filtrate, passive filtration of the small amount unbound in plasma through the glomerulus, and any reabsorption from the filtrate via OAT2/5 in rodents (OAT4 in humans) (Anzai et al., 2010).

Interindividual variability in transporter expression is a known mediator of variable pharmacokinetics, tissue distribution, and toxicity (Meier et al., 2006; Prasad et al., 2014). These changes are often a result of genetic polymorphisms, sex, age, and disease (Urakami et al., 1999; Yonezawa et al., 2005; Nakanishi and Tamai, 2012; Mooij et al, 2014). These changes are often a result of genetic polymorphisms, sex, age, and disease (Urakami et al., 1999; Yonezawa et al., 2005; Nakanishi and Tamai, 2012; Mooij et al, 2014). To induce hepatic inflammation consistent with a NASH phenotype, NASH mice were also administered thioacetamide (75 mg/kg i.p.) three times per week; thioacetamide was formulated at 10 mg/ml in sterile saline and then passed through a 0.2 μm filter. Water and test diets were available to mice ad libitum, and thioacetamide (for FFD/TH model mice only) was administered for 8 weeks to establish disease models.

To further understand changes to organic anion toxicokinetics and downstream effects on nephrotoxicity during NASH, we propose a fast food-dieted mouse with thioacetamide (FFD/TH) model to induce NASH. In this study, we demonstrate that reductions in renal OAT isoforms during NASH lead to increased urinary OTA clearance, and this in turn protects NASH mice from OTA-mediated nephrotoxicity.

Materials and Methods

Reagents. OTA and d5-OTA were purchased from Toronto Research Chemicals. Carboxymethyl cellulose, thioacetamide, and sodium deoxycholate were purchased from Sigma Aldrich. Liquid chromatography-mass spectrometry (LC-MS)-grade acetonitrile, water, ethyl acetate, and formic acid were purchased from Fisher Chemical. Sequencing-grade trypsin was purchased from Promega, Inc.

Animal Care and Use. All procedures were approved by the University of Arizona Institutional Animal Care and Use Committee and were carried out in accordance with the Guide for the Care and Use of Laboratory Animals. Five-week-old male C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, ME) and acclimated for 1 week in polycarbonate cages (three mice per cage). After acclimation, mice were randomly split into healthy and NASH cohorts: eight mice were fed choline-sufficient and iron-supplemented L-amino acid rodent diet (Dyets Inc., Model No. 518754) to maintain healthy phenotype, and eight mice were fed an amino acid-defined fast food diet (Test Diets, Model No. AIN-76A) to induce the NASH phenotype, as previously demonstrated (Sharma et al., 2019). To induce hepatic inflammation consistent with a NASH phenotype, NASH mice were also administered thioacetamide (75 mg/kg i.p.) three times per week; thioacetamide was formulated at 10 mg/ml in sterile saline and then passed through a 0.2 μm filter. Water and test diets were available to mice ad libitum, and thioacetamide (for FFD/TH model mice only) was administered for 8 weeks to establish disease models.

OTA Exposure, Toxicokinetics, and Disposition. OTA was diluted to 1.25 mg/ml in 0.25% carboxymethyl cellulose in water and then filter sterilized by passing through a 0.2 μm filter. Four animals each from healthy and NASH cohorts were administrated 12.5 mg/kg formulated OTA by oral gavage at t = 0 hours and then placed into metabolic cages; another four animals from each group were not exposed to OTA and were maintained as non-exposed-naïve cohorts. After exposure, approximately 10 μl of whole blood was collected by submandibular venipuncture into heparinized tubes at t = 0.5, 1, 2, 3, 6, 12, 24, and 48 hours postdose and then centrifuged for 15 minutes at 4 °C and 2000 × g to separate plasma. Urine was collected at 6, 24, 48, and 72 hours postdose by rinsing the metabolic cage with ~5 ml of water to collect any urine that dried onto the metabolic cage funnel. At 8 hours postdose, mice were administered subcutaneous sterile saline (10 ml/kg) to account for repeated blood loss at early time points. At 72 hours postdose, animals were sacrificed by carbon dioxide overdose and terminal blood was collected into heparinized needles by cardiac puncture. Kidney and liver tissues were collected and snap-frozen in liquid nitrogen; a small slice of both tissues was preserved in 10% neutral buffered formalin prior to dehydration and embedding in paraffin for histopathology. All plasma, urine, and tissue samples were stored at ~80 °C until processed.

LC-MS/MS Measurement of OTA. Pure OTA stock standards were diluted to 10 mg/ml in dimethyl sulfoxide and used for all analytical procedures. To measure plasma and urine OTA concentrations, pure OTA was diluted directly into blank biologic matrices at the following concentrations to serve as analytical standards: 0.5, 1, 5, 12.5, 25, 500, and 100 μg/ml for plasma and 0.05, 0.125, 0.25, 0.5, 1, and 5 μg/ml for urine. Unknown-mass samples were quantified against calibrators by spiking 2 μl of either sample or calibrator into 50 μl water with 0.1% formic acid containing d5-OTA (internal standard) at a concentration of 400 ng/ml. Both analytes were extracted from the aqueous phase by liquid-liquid extraction with 1.25 ml ethyl acetate. One milliliter of the organic phase was dried over air and then reconstituted in 100 μl of 20:80
acetonitrile:water with 0.1% formic acid prior to LC-MS/MS analysis. Unknown urine samples were quantified against calibrators by spiking 20 µl of either sample or calibrator into 200 µl water with 0.1% formic acid containing d5-OTA at a concentration of 50 ng/ml. Both analytes were extracted from the aqueous phase by liquid-liquid extraction with 1 ml ethyl acetate. Eight hundred microliters of organic phase were dried over air and then reconstituted in 100 µl of 20:80 acetonitrile:water with 0.1% formic acid prior to LC-MS/MS analysis. To measure tissue-bound OTA, a small slice of tissue was weighed and added to ice-cold 80:20 methanol:water with 200 ng/ml d5-OTA at a ratio of 0.5 ml per 25 mg tissue and homogenized using a rotary tissue grinder. Two hundred microliters were aliquoted and centrifuged for 10 minutes at 20,000 × g to remove debris; then 100 µl of supernatant was diluted with 1 ml water with 0.1% formic acid. Analytes were purified by liquid-liquid extraction with 1 ml ethyl acetate, vortexed, and then centrifuged for 2 minutes at 300 × g to separate phases. A 500 µl aliquot was dried over air and then reconstituted with 200 µl of 20:80 acetonitrile:water with 0.1% formic acid prior to LC-MS/MS analysis. To quantify OTA in unknown tissue samples, blank tissue (kidney or liver) was homogenized on ice in 10 mM tris buffer with protease inhibitor (Pierce) and then centrifuged to remove debris at 8000 × g for 1 hour at 4°C. The pellet was rinsed and then reconstituted with 10 µl tris buffer (pH 8.0); then 300 µg of protein was digested into digestion buffer containing 3.7% (w/v) sodium deoxycholate 100 mM ammonium bicarbonate. Protein was reduced at 95°C for 5 minutes with 6 µl dithiothreitol and then alkylated at room temperature in the dark with 15 mM iodoacetamide; the alkylation reaction was quenched with 20 µl dithiothreitol, and then peptides were digested with trypsin/Lys-C (Pierce) at 37°C overnight using an enzyme:substrate ratio of 1:100. The next day, the digestion reaction was quenched with 0.4% formic acid containing heavy-labeled peptide standards (Table 1) and centrifuged for 30 minutes at 20,000 × g and 4°C to remove detergent. Peptides were extracted and concentrated from the supernatants by strong cation exchange solid phase extraction (1 mg MCX cartridges, Waters, Inc.) following the manufacturer instructions. Eluted peptides were dried using a vacuum centrifuge and then reconstituted in 100 µl of water with 0.1% formic acid containing heavy isotope labeled amino acid internal standards (IS). RT indicates retention time for liquid chromatography method.

**Surrogate Peptide Quantification of OTA Transporters.** Kidney and liver tissue membrane fractions were prepared by ultracentrifugation and digested with trypsin; then unique surrogate peptides of OTA transporters were quantified by LC-MS/MS as previously described (Jilek et al., 2021). Briefly, tissue was homogenized on ice in 10 mM tris buffer with protease inhibitor (Pierce) and then centrifuged to remove debris at 8000 × g for 10 minutes. Supernatants were collected and membrane fractions were pelleted by ultracentrifugation at 100,000 × g for 1 hour at 4°C. The pellet was rinsed and then reconstituted with 10 µl tris buffer (pH 8.0); then 300 µg of protein was digested into digestion buffer containing 3.7% (w/v) sodium deoxycholate 100 mM ammonium bicarbonate. Protein was reduced at 95°C for 5 minutes with 6 µl dithiothreitol and then alkylated at room temperature in the dark with 15 mM iodoacetamide; the alkylation reaction was quenched with 20 µl dithiothreitol, and then peptides were digested with trypsin/Lys-C (Pierce) at 37°C overnight using an enzyme:substrate ratio of 1:100. The next day, the digestion reaction was quenched with 0.4% formic acid containing heavy-labeled peptide standards (Table 1) and centrifuged for 30 minutes at 20,000 × g and 4°C to remove detergent. Peptides were extracted and concentrated from the supernatants by strong cation exchange solid phase extraction (1 mg MCX cartridges, Waters, Inc.) following the manufacturer instructions. Eluted peptides were dried using a vacuum centrifuge and then reconstituted in 50 µl starting LC-MS/MS mobile phase conditions, and 10 µl was injected onto an Acquity UPLC HSS C18 column (Waters, Inc.) using an Agilent autosampler and then separated by binary gradient flow using water and acetonitrile with 0.1% formic acid as previously described (Jilek et al., 2021). Surrogate tryptic peptides were then detected on a Sciex Qtrap 6500+ triple quadrupole tandem mass spectrometer using multiple reaction monitoring (Table 1). Peak areas were integrated and quantified against pure peptide

**TABLE 1**

<table>
<thead>
<tr>
<th>Protein</th>
<th>Peptide Sequence</th>
<th>IS</th>
<th>RT min</th>
<th>Q1 [M + 2H]+ Da</th>
<th>Q3 [M + H]+ Da</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pgp</td>
<td>IATEAEINFR</td>
<td>BCRP-H</td>
<td>15.8</td>
<td>582.3</td>
<td>979.5</td>
</tr>
<tr>
<td>BCRP</td>
<td>ENLQFSAALR</td>
<td>BCRP-H</td>
<td>16.5</td>
<td>574.8</td>
<td>792.4</td>
</tr>
<tr>
<td>MRP2</td>
<td>GINLSGGQQK</td>
<td>MRP2-H</td>
<td>9.8</td>
<td>437.2</td>
<td>703.4</td>
</tr>
<tr>
<td>MRP3</td>
<td>QGELQLLRL</td>
<td>MRP2-H</td>
<td>10.0</td>
<td>366.2</td>
<td>501.3</td>
</tr>
<tr>
<td>MRP4</td>
<td>APVLFFDR</td>
<td>MRP4-H</td>
<td>19.9</td>
<td>482.8</td>
<td>697.4</td>
</tr>
<tr>
<td>OAT1</td>
<td>TSLAVLGLK</td>
<td>OAT1-H</td>
<td>14.0</td>
<td>394.7</td>
<td>600.4</td>
</tr>
<tr>
<td>OAT2</td>
<td>VGGFIPQQLR</td>
<td>MRP4-H</td>
<td>20.4</td>
<td>539.3</td>
<td>864.5</td>
</tr>
<tr>
<td>OAT3</td>
<td>DITSAK</td>
<td>MRP2-H</td>
<td>4.8</td>
<td>317.7</td>
<td>406.2</td>
</tr>
<tr>
<td>OAT5</td>
<td>ILSQDDLIR</td>
<td>BCRP-H</td>
<td>16.1</td>
<td>536.8</td>
<td>846.4</td>
</tr>
<tr>
<td>OATP4C1</td>
<td>DEPTAVK</td>
<td>OAT1-H</td>
<td>12.2</td>
<td>389.2</td>
<td>515.3</td>
</tr>
<tr>
<td>MRP2-H</td>
<td>GINL*SOGQQK</td>
<td></td>
<td>9.8</td>
<td>440.7</td>
<td>710.4</td>
</tr>
<tr>
<td>MRP4-H</td>
<td>TSLA*VLGK</td>
<td></td>
<td>20.4</td>
<td>486.3</td>
<td>704.4</td>
</tr>
<tr>
<td>BCRP-H</td>
<td>ENLQFSA*ALR</td>
<td></td>
<td>16.5</td>
<td>576.9</td>
<td>668.4</td>
</tr>
<tr>
<td>OAT1-H</td>
<td>TSLA*VLGK</td>
<td></td>
<td>14.0</td>
<td>396.7</td>
<td>491.3</td>
</tr>
</tbody>
</table>

Multiple reaction monitoring transitions used for detection are listed as doubly charged parent ion (Q1) and singly charged fragment ion (Q3) used for quantification. * Indicates 13C/16N heavy isotope labeled amino acid internal standards (IS). RT indicates retention time for liquid chromatography method. (Q3) indicates that no IS was used.
standards (Table 1) and protein abundance was converted to picomole per milli-
gram (pmol/mg) protein using the following equation:

\[
\text{Protein Abundance (pmol/mg Protein)} = \frac{\text{Surrogate Peptide (pg)}}{\text{Peptide MW (g/mol)}} \times \frac{1}{\text{Peptide Input (mg)}}
\]

Pharmacokinetics Modeling and Data Analysis. Plasma OTA pharmacokinetic parameters were derived by the area under the plasma concentration-time curve (AUC) method using Phoenix WinNonlin version 8.1 (Certara, Inc.). Renal excretion as a percentage of dose was calculated by the percentage of total amount of OTA eliminated into the urine over 72 hours to the bolus dose by oral gavage. Grouped analysis represents mean values ± S.D. Means were compared using two-tailed Student’s t test or analysis of variance (ANOVA) where appropriate (GraphPad Prism 9.0); comparisons were considered significantly different when \( P < 0.05 \).

Histopathology. Kidney samples were fixed in 10% neutral-buffered formalin prior to routine processing and paraffin embedding. Tissue sections (5 μm) were stained with hematoxylin and eosin and examined/analyzed by a board-certified veterinary pathologist. Renal sections were examined for necrosis, degeneration, vacuolation, regeneration, tubular dilation, epithelial cell loss, and glomerular changes. Semiquantitative severity scores were as follows: 0, none; 1, minimal with less than 10% affected; 2, mild with 10%–25% affected; 3, moderate with 25%–40% affected; 4, marked with 40%–50% affected; and 5, severe with over 50% affected.

Results

NASH Mice Display Reduced OTA-Associated Nephrotoxicity. After a single 12.5 mg/kg bolus dose of OTA (by mouth), healthy and NASH mice lost 7.00% ± 2.63% and 15.68% ± 1.20% of baseline body weight, respectively, suggesting that OTA may be generally less toxic in NASH mice (Fig. 1). At sacrifice, both kidney and liver masses of control mice decreased by approximately 12% and 30% more than those of NASH mice treated with the same dose of OTA per kg of body weight (Fig. 1). These findings were supported by histopathological lesions in the kidney but not in the liver of OTA-exposed treatment groups. Specifically, necrosis scores increased significantly from minimal (score of 1) in
NASH mice to mild (score of 2) in healthy mice (Figs. 2 and 3). Similar significant histopathological trends were observed for the endpoint of proximal convoluted tubule cell vacuolation with reduced findings in the NASH/OTA group when compared with the healthy/OTA group (Fig. 3). Furthermore, degeneration of proximal convoluted tubule epithelial cells was decreased where half of the NASH mice presented with no degenerative lesions, whereas all healthy mice exhibited at least mild degenerative lesions in response to OTA (Fig. 3). There were no histopathological findings in OTA-naïve mice.

OTA Renal Excretion Increases in NASH Mice. To probe the differential nephrotoxicity induced by OTA in healthy and NASH mice, tissue distribution and OTA elimination were compared between both groups. Although individual mean plasma OTA concentrations over 72 hours did not vary significantly between groups, the plasma concentration-time curve trended upwards in the NASH mice, relative to healthy mice (Fig. 4). This was confirmed by a significant increase in dose-normalized plasma AUC last from 5.65 ± 1.10 mg·h/ml per mg OTA in healthy animals to 13.11% ± 3.10% in NASH mice (Table 2). However, the observed dose-normalized C max in both groups was nearly identical at approximately 200 µg/ml per mg OTA, and the elimination half-life did not change significantly either. Notably, these changes were reflected in an approximately 33% decrease in apparent volume of distribution, suggesting that OTA may be accumulating in tissues at a greater rate in healthy animals (Table 2). As such, kidney- and liver-bound OTA increased significantly in healthy animals by approximately 30% in both tissues, relative to NASH animals (Fig. 5).

Although systemic rates of elimination did not vary between both groups, the cumulative percentage of OTA eliminated into the urine robustly increased in NASH animals, and this difference became significant at 48 hours postdose (Fig. 4). At sacrifice, the total amount of OTA eliminated into the urine in NASH mice was nearly 2-fold higher than in healthy mice (Table 2). This change was reflected in a significant increase in renal excretion from 5.55% ± 0.37% in healthy mice to 13.11% ± 3.10% in NASH mice (Table 2).

NASH Induces Changes to OTA Transporters. Given changes to renal excretion and disposition of OTA, renal and hepatic transporter expression was quantified to probe a possible molecular mechanism for this difference. Using a surrogate peptide LC-MS/MS method, known organic anion transporters were absolutely quantified from renal and hepatic membrane fractions (Fig. 6). Notably, all OAT isoforms in the kidney decreased to various degrees and OAT2 in the liver decreased modestly in the NASH mice. Basolateral renal OTA uptake transporters, OAT1 and OAT3, decreased in NASH mice from 0.37 ± 0.07 to 0.19 ± 0.09 pmol/mg protein and 1.02 ± 0.43 to 0.29 ± 0.13 pmol/mg protein, respectively. Expression of OAT2 also decreased in the kidney and liver of NASH mice from 2.20 ± 0.19 to 1.22 ± 0.46 pmol/mg protein and from 3.03 ± 0.41 to 2.39 ± 0.30 pmol/mg protein, respectively. Lastly, NASH mice displayed a robust decrease of the apically expressed renal OAT5 transporter from 1.12 ± 0.09 to 0.49 ± 0.19 pmol/mg protein, relative to healthy mice. Interestingly, P-glycoprotein (P-gp) increased significantly in renal tissue of NASH mice from an extremely low abundance to approximately 1.25 pmol/mg protein, suggesting that it may be induced in this tissue during NASH (Fig. 6). Furthermore, renal MRP2 decreased by approximately half in NASH mice, relative to healthy, although hepatic MRP2 increased modestly in NASH mice. Lastly, BCRP, MRP3, and MRP4, which facilitate active organic anion export, did not change between NASH and healthy animals.

Discussion

The current understanding of the mechanism of OTA renal elimination is proposed to be the sum of active OAT1- and OAT3-mediated secretion into the proximal tubule cells and glomerular filtration of unbound OTA, less any OAT2- and OAT5-mediated uptake from the filtrate back into the proximal convoluted tubule cell (Anzai et al., 2010). Given the dramatic decreases of all OAT transporters (Fig. 6), these data suggest that renal secretion and reabsorption are functionally limited in NASH mice, reducing the exposure of the proximal tubule cell to OTA. Additionally, glomerular filtration removes the small fraction of OTA that is unbound to plasma proteins, and our data suggest that the OAT2 and 5 decreases in NASH animals (Fig. 6) reduce the amount reabsorbed. As such, we observed an increase in the cumulative OTA eliminated into the urine (Fig. 4), reflected in a significant increase in OTA renal excretion (Table 2). These observations are further supported by evidence that less OTA is bound to renal tissue in NASH mice, relative to healthy mice (Fig. 5), and that this also manifests in significant decreases in nephrotoxic lesions in NASH mice (Figs. 1 and 2).

**TABLE 2**

Pharmacokinetic parameters in healthy and NASH rats administered 12.5 mg/kg OTA

<table>
<thead>
<tr>
<th></th>
<th>t1/2 h</th>
<th>Cmax/D µg·ml⁻¹/mg⁻¹</th>
<th>AUClast/D mg·h·ml⁻¹/mg⁻¹</th>
<th>V/F ml</th>
<th>CL/F ml·h⁻¹</th>
<th>A0 µg</th>
<th>A0 % of dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>62.46 ± 17.04</td>
<td>199.80 ± 79.25</td>
<td>5.65 ± 1.10</td>
<td>8.28 ± 1.51</td>
<td>0.10 ± 0.03</td>
<td>24.41 ± 1.74</td>
<td>5.55 ± 0.37</td>
</tr>
<tr>
<td>NASH</td>
<td>53.17 ± 19.38</td>
<td>196.90 ± 52.51</td>
<td>7.95 ± 0.61*</td>
<td>5.44 ± 0.41*</td>
<td>0.08 ± 0.02</td>
<td>40.07 ± 9.19*</td>
<td>13.11 ± 3.10*</td>
</tr>
</tbody>
</table>

A0, amount excreted into urine over 72 h; AUC last, area under the plasma concentration-time curve measured from 0 to 72 h; CL/F, apparent systemic clearance; Cmax, maximal plasma concentration; D, dose; t1/2, elimination half-life; V/F, apparent volume of distribution.

* Indicates P < 0.05.
Taken together, these findings support a mechanistic protective effect of NASH-induced renal transporter phenoconversion.

OAT2 and 5 function is bidirectional (Anzai et al., 2005), consistent with other OAT isoforms, and in theory may function to secrete OTA into the filtrate via transepithelial transport after OAT1 and 3 uptake, in addition to reabsorption from the filtrate. As such, reduced OAT 2 and 5 expression in NASH mice (Fig. 6) exposed to OTA could either 1) sequester OTA that has been taken up by basolateral OATs in proximal convoluted tubule cells or 2) have a reduced capacity to reabsorb OTA from the tubular lumen. Although the data presented in this work do not prove the directionality of OAT2/5-mediated net OTA transport, these data suggest that OAT2/5 reductions induced by NASH reduce reabsorption into the proximal convoluted tubule cells.

NASH mice in this study demonstrated a significant decrease in basolateral OAT1/3 (Fig. 6), which may reduce proximal tubule cell disposition, as observed (Fig. 5). This may contribute to the observed reduction in nephrotoxicity in NASH mice (Fig. 3), as the plasma AUC also increased modestly (Table 2). However, average plasma concentrations at specific timepoints did not significantly differ between NASH and healthy animals (Fig. 4), nor did the rate of plasma OTA clearance (Table 2). Additionally, OTA is extensively plasma protein-bound, reducing the available pool of systemic OTA available for glomerular filtration and transport-mediated secretion (Rinog et al., 2006). Given the long elimination half-life in most species, including mice used in this study ($t_{1/2}$ of ~50–60 hours, Table 2), it is unlikely that renal proximal tubule cells can accumulate a significant concentration gradient to shift the transport equilibrium to favor export of OTA. As such, these data, in addition to OTA physiochemical properties, suggest that reabsorption is a major driver of OTA nephrotoxicity.

Transport of OTA across biologic barriers is somewhat well understood; however, significant species differences exist. OAT5 is one of the primary apical OTA transporters, although it is not expressed in humans; likewise, OAT4 has significant substrate overlap with OAT5, including OTA, and is also expressed on the luminal membrane, but it is not expressed in rodents (Nigam et al., 2015; Ivanuyk et al., 2017). As such, although rodent OAT5 and human OAT4 share functional similarities, they are not true orthologs. Furthermore, although OAT2 expression is very low in the human kidney, our data suggest that absolute expression is appreciable in the mouse kidney (Fig. 2; Basit et al., 2019). Additionally, OAT2 expression in humans is localized to the basolateral membrane, whereas in rodents it is localized to the apical membrane (Ljubojevic et al., 2007; Nigam et al., 2015). Thus, while OAT4/5-dependent OTA reabsorption from the luminal filtrate is somewhat well studied, this species difference in rodents is not. Lastly, new OTA renal transporters are being identified, including human sodium/phosphate cotransporter 4 (hNPT4) (Jutabha et al., 2011); however, functional orthologs in rodents have not been identified to date.

Taken together, these results provide evidence suggesting that NASH-mediated decreases in several OAT isoforms reduce the kidney’s capacity to accumulate OTA in an FFD/TH mouse model of NASH, thus reducing its nephrotoxicity. Additionally, as a major mechanism of organic anion clearance, NASH-induced disruptions to OAT

---

**Fig. 5.** NASH reduces kidney and liver disposition of a single OTA exposure. After 72 hours, the relative amount of OTA in kidney and liver tissue was measured by LC-MS/MS as described in Materials and Methods. Data points represent individual animal values, and horizontal bars represent mean values ± S.D. of $n = 4$ animals per group. Mean values were compared by unpaired two-tailed Student’s $t$ test where * indicates $P < 0.05$.

**Fig. 6.** OTA uptake transporter expression is altered in NASH mice. Transporter expression in liver and kidney tissue was evaluated by quantifying surrogate peptides. NASH animals showed significant decreases in basolateral OAT1 and 3 and apical OAT2 and 5 OTA uptake transporter expression. No significant changes were found in BCRP, MRP3, or MRP4 expression, which also catalyze OTA efflux, whereas renal P-gp and hepatic MRP2 expression increased. Data points represent individual animal values, and horizontal bars represent mean values ± S.D. of $n = 4$ animals per group. Mean values were compared by unpaired two-tailed Student’s $t$ test where * indicates $P < 0.05$. 
expression likely affect renal elimination of other drugs and toxicants with similar physiochemical profiles. As such, this work highlights the importance of changes to reabsorption pathways, in addition to filtration and secretion during NASH, which may influence xenobiotic clearance, efficacy, or toxicity.

Authorship Contributions

Participated in research design: Jilek, Wright, Cherrington.
Conducted experiments: Jilek, Frost, Marie, Myers, Goedken.
Contributed new reagents or analytic tools: Jilek.
Performed data analysis: Goedken.
Wrote or contributed to the writing of the manuscript: Jilek, Frost, Marie, Myers, Goedken, Wright, Cherrington.

References


Address correspondence to: Dr. Nathan J. Cherrington, Department of Pharmacology and Toxicology, University of Arizona, College of Pharmacy, 1703 E. Mable Street, Tucson, AZ 85719. E-mail: cherrington@pharmacy.arizona.edu